Isufi Iris, Seetharam Mahesh, Zhou Li, Sohal Davendra, Opalinska Joanna, Pahanish Perry, Verma Amit
Albert Einstein College of Medicine, Bronx, NY 10461, USA.
J Interferon Cytokine Res. 2007 Jul;27(7):543-52. doi: 10.1089/jir.2007.0009.
Transforming growth factor-beta (TGF-beta) is an important physiologic regulator of cell growth and differentiation. TGF-beta has been shown to inhibit the proliferation of quiescent hematopoietic stem cells and stimulate the differentiation of late progenitors to erythroid and myeloid cells. Insensitivity to TGF-beta is implicated in the pathogenesis of many myeloid and lymphoid neoplasms. Loss of extracellular TGF receptors and disruption of intracellular TGF-beta signaling by oncogenes is seen in a variety of malignant and premalignant states. TGF-beta can also affect tumor growth and survival by influencing the secretion of other growth factors and manipulation of the tumor microenvironment. Recent development of small molecule inhibitors of TGF-beta receptors and other signaling intermediaries may allow us to modulate TGF signaling for future therapeutic interventions in cancer.
转化生长因子-β（TGF-β）是细胞生长和分化的重要生理调节因子。TGF-β已被证明可抑制静止造血干细胞的增殖，并刺激晚期祖细胞向红细胞和髓细胞分化。对TGF-β不敏感与许多髓系和淋巴系肿瘤的发病机制有关。在多种恶性和癌前状态中可见细胞外TGF受体的缺失以及癌基因对细胞内TGF-β信号传导的破坏。TGF-β还可通过影响其他生长因子的分泌和调控肿瘤微环境来影响肿瘤的生长和存活。TGF-β受体及其他信号中介物的小分子抑制剂的最新进展可能使我们能够调节TGF信号传导，以便未来对癌症进行治疗干预。
